Interacting Drugs |
Tranexamic acid vs Fibrinogen Concentrate (Human) |
Security Level |
 |
Mechanism |
Fibrinogen Concentrate (Human): Antifibrinolytic Agents may enhance the adverse/toxic effect of Fibrinogen Concentrate (Human). Specifically, the risk for thrombosis may be increased. Fibrinogen Concentrate (Human) may enhance the adverse/toxic effect of Antifibrinolytic Agents. Specifically, the risk for thrombosis may be increased. |
Management |
Monitor therapy |
Tranexamic acid vs Fibrinogen Concentrate (Human)
Post Review about Tranexamic acid vs Fibrinogen Concentrate (Human) Click here to cancel reply.
Other Interactions of Tranexamic acid
Other Interactions of Fibrinogen Concentrate (Human)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.